| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA1163: Nogapendekin alfa inbakicept with BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG (terminated evaluation) |
|
Medicine details |
|
| Medicine name | Nogapendekin alfa inbakicept (ANKTIVA®) |
| Formulation | Solution for injection |
| Reference number | 7180 |
| Indication | In combination with BCG for non-muscle-invasive bladder cancer with carcinoma in situ that is unresponsive to BCG |
| Company | Serum Life Science Europe GmbH |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Advice number | TA1163 |
| Date of issue | 05/06/2026 |
| NICE guidance | |